GB Sciences Launches Global Expansion in Canada with GBS Global Biopharma, Inc.

Published: March 20, 2019

GB Sciences Launches Global Expansion in Canada with GBS Global Biopharma, Inc.

GB Sciences, Inc. launched a global expansion strategy with the formation of GBS Global Biopharma Inc., a cannabinoid medicine company based in Canada. GBS Global will expedite the development of clinical programs and IP currently indicated for 60 disease and health conditions.

The company is dedicated to developing cannabinoid medicines for medical cannabis, nutraceutical, and prescription drug markets. The Canadian entity will operate in a fully legal, open business environment allowing for greater international collaboration, cross border expansion, access to capital, and cost-effective R&D supported by the country’s legal market, tax credits and favorable exchange rates.

GBS Global proprietary discovery platform generates “complex mixture” cannabinoid/terpenoid active ingredients (APIs) for specific disease and health conditions. GBS Global researchers are working with scientists in the United States, Spain, and Greece on nutraceuticals, delivery technology, and prescription drug programs.

“Canada’s policies will allow GBS Global to bring our next-generation cannabinoid medications to market quickly, safely and legally. Canada’s regulations, in particular, mean treatments can be evaluated and approved in less time than it would take in the U.S.,” said GBS Global Board Chair and CEO of GB Sciences, Inc. John Poss. “This creates vital new opportunities for GBS Global, benefitting both our patients and investors.”

GBS Global intellectual property portfolio of natural and synthetic cannabinoid-based complex mixtures are indicated for Parkinson’s (PD), neuropathic pain, and cardiac hypertrophy Rx programs in late pre-clinical stage of development. OTC programs for irritable bowel syndrome, sleep disorders, and psoriasis are at formulation stage in step with ongoing discussions with strategic partners in the field.

“Developing our life sciences assets in Canada will expedite work to validate the safety and effectiveness of our proprietary therapeutics through expanded access to research partners and capital,” said Dr. Andrea Small-Howard, Chief Science Officer and Board Member of GBS Global. “In addition, Canada’s medical cannabis legislation provides an alternative channel for supporting health claims on some of our OTC patent-pending formulas. Plus, these products can be exported to Europe, the world’s fastest growing market.”

Recent News

View All News Items

Latest Article

How Database Integrations Can Improve Every Step in Your Cannabis Supply Chain Labeling

How Database Integrations Can Improve Every Step in Your Cannabis Supply Chain Labeling

At any step in the cannabis supply chain, your labeling system should allow for full control and traceability, from seed to sale. Implementing lean principles and labeling best practices across the cannabis supply chain can help you streamline your seed-to-sale labeling process and help you gain control.

Click below to read the full blog and learn how to reduce waste, cut costs, and gain efficiency with cannabis labeling: https://bit.ly/2KwZ5IQ

Read Article